Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Average Recommendation of "Buy" from Analysts

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) has been given an average recommendation of "Buy" by the six ratings firms that are presently covering the firm, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $19.50.

ZVRA has been the topic of several research analyst reports. William Blair reissued an "outperform" rating on shares of Zevra Therapeutics in a research note on Tuesday, March 12th. HC Wainwright restated a "buy" rating and issued a $15.00 target price on shares of Zevra Therapeutics in a research note on Wednesday, April 3rd. Maxim Group boosted their target price on Zevra Therapeutics from $12.00 to $18.00 and gave the company a "buy" rating in a research report on Tuesday, April 2nd. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Zevra Therapeutics in a report on Monday, April 1st.

Hedge Funds Weigh In On Zevra Therapeutics

Several large investors have recently added to or reduced their stakes in ZVRA. VisionPoint Advisory Group LLC purchased a new stake in shares of Zevra Therapeutics in the third quarter worth approximately $33,000. International Assets Investment Management LLC raised its position in Zevra Therapeutics by 555.0% in the 4th quarter. International Assets Investment Management LLC now owns 6,550 shares of the company's stock valued at $43,000 after buying an additional 5,550 shares during the last quarter. Commonwealth Equity Services LLC purchased a new stake in Zevra Therapeutics in the 3rd quarter valued at $52,000. Kingsview Wealth Management LLC bought a new position in Zevra Therapeutics during the 3rd quarter valued at $58,000. Finally, Tower Research Capital LLC TRC boosted its holdings in Zevra Therapeutics by 134.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 9,673 shares of the company's stock worth $63,000 after acquiring an additional 5,545 shares during the last quarter. Institutional investors own 35.03% of the company's stock.

Zevra Therapeutics Trading Up 3.8 %

Shares of NASDAQ:ZVRA traded up $0.17 during midday trading on Friday, reaching $4.66. The company's stock had a trading volume of 164,760 shares, compared to its average volume of 188,522. Zevra Therapeutics has a fifty-two week low of $3.89 and a fifty-two week high of $7.28. The company has a debt-to-equity ratio of 0.88, a quick ratio of 2.10 and a current ratio of 2.10. The firm has a 50 day moving average price of $4.99 and a two-hundred day moving average price of $5.41. The firm has a market capitalization of $195.02 million, a price-to-earnings ratio of -3.45 and a beta of 1.87.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last issued its quarterly earnings results on Thursday, March 28th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.20). The business had revenue of $13.22 million during the quarter, compared to analyst estimates of $13.35 million. Zevra Therapeutics had a negative net margin of 181.76% and a negative return on equity of 82.55%. As a group, analysts forecast that Zevra Therapeutics will post -1.54 earnings per share for the current year.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.